Repligen Completes Expansion of U.S. Manufacturing Facility
News Nov 07, 2013
Repligen Corporation has announced that it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met.
A dedicated production suite more than doubles capacity for the Company's OPUS® line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers.
"This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen.
Herlihy continued, "The new cleanroom suite enables us to produce OPUS® columns under the highest quality standard demanded by biopharmaceutical manufacturers."
The facility expansion also triples warehouse space and includes dedicated purification and fermentation laboratories for optimization of existing manufacturing processes, new product development and applications support.
An additional 17,000 square feet is reserved for future expansion of the same facility, allowing the Company to remain flexible and responsive to the needs of its biopharmaceutical customers and life sciences partners.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE